<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04049630</url>
  </required_header>
  <id_info>
    <org_study_id>C18-58</org_study_id>
    <nct_id>NCT04049630</nct_id>
  </id_info>
  <brief_title>Clinical Trial Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients</brief_title>
  <acronym>EOLoa</acronym>
  <official_title>Randomized Clinical Trial, Double-blind, Dose-escalating of Drug Intensities, Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at evaluating the safety and efficacy of levamisole in patients with loiasis
      infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial will be conducted in Republic of Congo. This is a randomized,
      double-blind clinical trial. Levamisole will be tested at 1 and 1,5 mg/kg, and compared to
      placebo (50:50:50). We will perform three cohorts of patients according to the microfilarial
      density : 500-1,999 mf/ml, 2,000-7,999 mf/ml, and 8,000-20,000 mf/ml.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 15, 2020</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of levamisole</measure>
    <time_frame>1 week</time_frame>
    <description>Absence of severe adverse events during the first week</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events with levamisole</measure>
    <time_frame>1 week</time_frame>
    <description>Proportion of adverse events during the first week</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of levamisole</measure>
    <time_frame>Day 2, Day 7, and Month 1</time_frame>
    <description>Proportion of reduction of the microfilarial density of Loa loa at Day 2, Day 7, and Month 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of individuals without microfilariae of Loa loa</measure>
    <time_frame>Day 7 and 1 Month</time_frame>
    <description>Proportion of individuals with a diminution of 80% and more of the microfilarial density at Day 7 and Month 1</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Onchocerciasis, Ocular</condition>
  <condition>Loiasis</condition>
  <arm_group>
    <arm_group_label>LEV 1 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablets of LEV at 1 mg/kg will be administrated to the participant ; in single dose only one time. The number of tablets of LEV of 50 mg or 10 mg will be adapted according to the weight of the participant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LEV 1,5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablet of LEV at 1,5 mg/kg will be administrated to the participant ; in single dose only one time. The number of tablets of LEV of 50 mg or 10 mg will be adapted according to the weight of the participant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tablets of placebo will be administrated to the participant in single dose only one time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEV 1 mg/kg</intervention_name>
    <description>A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.</description>
    <arm_group_label>LEV 1 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEV 1,5 mg/kg</intervention_name>
    <description>A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.</description>
    <arm_group_label>LEV 1,5 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>5 tablets of placebo will be administrated to the participants.</description>
    <arm_group_label>LEV 1 mg/kg</arm_group_label>
    <arm_group_label>LEV 1,5 mg/kg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written consent written, signed (or with thumbprint) and dated

          -  Aged 18 to 65 inclusive

          -  Individual microfilarial density ≥ 500 mf/mL

          -  Body weight ≥ 40 kg in women and ≥ 45 kg in men; and less than 85 kg

          -  In good health condition, as determined by the medical questionnaire and the general
             clinical examination: absence of acute or chronic infection

        Exclusion Criteria:

          -  Participation in any study other than purely observational, in the 4 weeks preceding
             this study (determined by the theoretical date of administration of LEV or placebo).

          -  Any vaccination in the 4 weeks preceding this study.

          -  Acute infection requiring a treatment in the 10 days preceding this study, determined
             by the anamnesis during the medical interview (example: pulmonary infection, ENT,
             digestive, cutaneous, with implementation of an antibiotic treatment or not)

          -  Warfarin treatment

          -  Treatment with clozapine, phenythiazines, sulfasalazine, carbamazepine, synthetic
             antithyroid, ticlopidine, cimetidine, and gold salts: whether it is a long-term
             treatment, or a treatment given in a single dose 10 days before the start of treatment
             for the clinical trial (precaution of use compared to the risk of agranulocytosis of
             immuno-allergic or toxic origin)

          -  Known immunosuppressive pathology

          -  Past or current history of neurological (including epilepsy) or neuropsychiatric
             disease

          -  History of agranulocytosis

          -  Consumption of alcohol, taking cocaine or other drugs of abuse in the 72 hours
             preceding the administration of the treatment of the test determined by the anamnesis
             during the medical interview

          -  Any condition, in the opinion of the investigator, which exposes the subject to an
             undue risk

          -  Known intolerance to levamisole

          -  Subjects who gave blood in the 8 weeks before entry into the study, with a standard
             volume (&gt; 500 mL)

          -  During the clinical examination: symptoms, physical signs or biological constants
             suggestive of systemic disorders, including renal, hepatic, cardiovascular, pulmonary,
             cutaneous, immunodeficiency, psychiatric disorders and other abnormalities likely to
             interfere with the interpretation results of the test. The doctor may then give a
             favorable or unfavorable opinion for the inclusion of the participant

          -  Taking IVM and / or LEV during the last six months; and / or mebendazole or
             albendazole in the last month

          -  Pregnant and lactating women (based on self-declaration)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cédric Chesnais, MD</last_name>
    <phone>+33467416162</phone>
    <email>cedric.chesnais@ird.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Secteur opérationnelle de la Santé, Ministère de la Santé et de la Population</name>
      <address>
        <city>Sibiti</city>
        <country>Congo</country>
      </address>
    </facility>
    <contact>
      <last_name>François Missamou, MD</last_name>
      <email>francmissamou2009@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Charlotte Bizet, PharmD</last_name>
      <email>charlotte.bizet@ird.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Francois Missamou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Congo</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 26, 2019</study_first_submitted>
  <study_first_submitted_qc>August 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2019</study_first_posted>
  <last_update_submitted>August 6, 2019</last_update_submitted>
  <last_update_submitted_qc>August 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onchocerciasis</mesh_term>
    <mesh_term>Onchocerciasis, Ocular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

